坏死性软组织感染临床试验复合终点的验证
本研究定义并验证了坏死性软组织感染(NSTI)的复合终点NICCE,包含28天存活、14天前清创≤3次、首次清创后无截肢、14天mSOFA≤1,全部满足为成功。采用2013年12家美国创伤中心198例回顾性数据、其中入院mSOFA≥3的69例亚组,以及CD28免疫调节剂AB103多中心2期随机试验40例数据评估效度。全部患者与高病情严重度亚组的NICCE成功率分别为58%与33%;NICCE成功者ICU-free天数与脱机天数均更高。2期数据中AB103组(0.5 mg/kg,n=15)NICCE成功率73.3%,安慰剂组(n=10)40%。作者认为NICCE内部一致性和面效度、标准效度良好,可用于NSTI临床试验。
要点
- NICCE需同时满足:28天存活、14天前清创≤3次、首次清创后无截肢、14天mSOFA≤1,全部满足才算成功。
- 198例回顾性数据中全部患者NICCE成功率58%,入院mSOFA≥3的69例亚组仅33%。
- NICCE成功者ICU-free天数中位25.3天(IQR 21.9-28)vs 失败者19.6天(IQR 4.3-25.1),单侧Wilcoxon P<0.001。
- NICCE成功者脱机天数中位28天(IQR 26-28)vs 失败者25天(IQR 14-28),P<0.001。
- 2期试验中AB103组(0.5 mg/kg,n=15)NICCE成功率73.3%,安慰剂组(n=10)40%。
适用人群与场景
- 坏死性软组织感染患者,数据来自2013年12家美国创伤中心回顾性数据集198例,以及其中入院mSOFA评分≥3的高病情严重度亚组69例。
- 另纳入多中心2期随机试验中接受CD28免疫调节剂AB103或安慰剂的40例患者(AB103组n=15,安慰剂组n=10)。
诊断标准与关键阈值
- NICCE定义为同时满足以下四项:(i)第28天存活;(ii)第14天前清创次数≤3次;(iii)首次清创后无截肢;(iv)第14天mSOFA评分≤1。全部个体标准均满足才判定为成功。
研究设计与关键结果
- 研究类型为复合终点验证研究,使用回顾性数据集(198例,12家美国创伤中心,2013年治疗)及多中心2期随机试验数据(40例)。
- 全部患者与高病情严重度亚组(入院mSOFA≥3,n=69)分别:存活率92%与84%;第14天mSOFA≤1为69%与51%;清创≤3次为84%与77%;首次清创后无截肢为96%与94%。
- NICCE全部成功标准满足率:全部患者58%,入院mSOFA≥3亚组33%。
- NICCE成功vs失败:ICU-free天数中位25.3天(IQR 21.9-28)vs 19.6天(IQR 4.3-25.1),单侧Wilcoxon P<0.001;脱机天数中位28天(IQR 26-28)vs 25天(IQR 14-28),P<0.001。
- 2期试验数据:AB103组(0.5 mg/kg,n=15)NICCE成功率73.3%,安慰剂组(n=10)40%。
证据类型、等级与局限
- 证据类型:复合终点验证研究,使用回顾性数据集与2期随机试验数据;证据等级:预后/流行病学level III,治疗level IV。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为NICCE各组分内部一致,具有面效度和标准效度,为坏死性软组织感染临床试验提供展示临床相关治疗效应的机会。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Our objective was to develop and validate a composite endpoint for patients with necrotizing soft tissue infections that incorporates: local tissue injury, systemic organ dysfunction, and mortality.
METHODS: The Necrotizing Infection Clinical Composite Endpoint (NICCE) was defined as follows:(i) alive at day 28, (ii) three or less debridements before day 14, (iii) no amputation beyond first debridement, (iv) modified sequential organ failure assessment score score (mSOFA) at day 14 ≤ 1. To be considered a success, all individual criteria must be met. Several data sets were used to assess validity: (i) a retrospective data set of 198 patients treated during 2013 at 12 US trauma centers; (ii) a subset with high disease acuity, admission mSOFA score of 3 or higher (n = 69); and (iii) 40 patients from a multicenter, phase 2 randomized trial of a CD28 immunomodulator (AB103). Clinical success based on each parameter and the composite score was assessed.
RESULTS: Using the retrospective data set for all patients and those with high disease severity (respectively), survival rates were 92% and 84%; day 14 mSOFA 1 or lower score was 69% and 51%; three or less debridements was 84% and 77%; and no subsequent amputations were 96% and 94%. Overall, the percent meeting all success criteria for NICCE was 58% (all patients) and 33% (mSOFA > 3). NICCE success was also associated with reduced utilization of health care resources, intensive care unit-free days were median (interquartile range) of 25.3 (21.9-28) and 19.6 (4.3-25.1) days (one-sided Wilcoxon p < 0.001) and ventilator-free days were 28 (26-28) versus 25 (14-28) (p < 0.001) for NICCE success versus failure, respectively. Using the phase 2 data set, the treated group (0.5 mg/kg, n = 15) demonstrated a NICCE success rate of 73.3% versus 40% for placebo (n = 10).
CONCLUSION: These data demonstrate internal consistency of the components and face and criterion validity of the NICCE endpoint. NICCE offers an opportunity to demonstrate a clinically relevant treatment effect for patients enrolled in clinical trials for necrotizing soft tissue infection.
LEVEL OF EVIDENCE: Prognostic/Epidemiological, level III; Therapeutic, level IV.
参考来源
- Bulger EM, May A, Dankner W, et al. Validation of a clinical trial composite endpoint for patients with necrotizing soft tissue infections. J Trauma Acute Care Surg. 2017. PMID: 28538644. doi:10.1097/TA.0000000000001564
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。